Full wire
Times are UTC. Priority tells you how much a story changes things. What the levels mean
Torrent Pharmaceuticals says it hopes to sell semaglutide in Brazil within six to nine months after Brazil revenue rose 38% in rupees and 20% in local currency. No regulatory filing or approval has been disclosed.
AHMEDABAD · Medical Dialogues report on Torrent Pharmaceuticals Q2 FY27 earnings call, 26 Oct 2026, crediting The Hindu BusinessLine
Pharmacists say the HHS policy offers a safer route than the gray market for six unapproved peptides. Pharmacologists say none has passed FDA testing, and it is unclear how long the policy lasts or whether outsourcing facilities are covered.
WASHINGTON · Everyday Health report carried by Yahoo News, 29 Oct 2026, citing the HHS enforcement discretion policy on 503A peptide compounding dated 28 Oct 2026
A pharmacist and three physicians told Yahoo Health that people on GLP 1 drugs should rethink NSAIDs, sedating antihistamines and combination cold products. The FDA's Wegovy label ties most kidney injury reports to dehydration.
NEW YORK · Yahoo Health report, 30 Oct 2026; FDA Wegovy prescribing information, Aug 2025 revision
A 32 year old Australian woman told ABC News she developed acute liver failure days after injecting a vial labelled retatrutide, an experimental drug the FDA says has not been found safe and effective for any condition.
NEW YORK · New York Post report citing ABC News Australia, 30 Oct 2026; FDA statement on unapproved GLP-1 drugs, updated 1 Oct 2026
NielsenIQ says the grocery baskets of people who stop GLP 1 drugs largely revert to non-user patterns within six to 11 months. Hy-Vee is betting on a dietitian-backed course, while trials show most people regain weight after stopping.
UNITED STATES · Food Dive report by Peyton Bigora, 30 Oct 2026, citing NielsenIQ, Numerator and Hy-Vee CEO Jeremy Gosch; trial context from JAMA Internal Medicine (SURMOUNT-4 post hoc, Nov 2025)
Dr Reddy's CFO says the company is counting on semaglutide and an abatacept biosimilar for its next growth phase. Supply stopped in July after an impurity in scale up API batches, and the new pen target is about half the old one.
HYDERABAD · Moneycontrol interview with CFO M.V. Narasimham, 25 Oct 2026; Dr Reddy's semaglutide update call transcript in SEC filing, 9 Jul 2026
PolyPeptide shareholders backed all board proposals, electing five directors and voting to remove transfer and voting limits. Each step depends on the Samsung Peptide AG tender offer, and the release gives no price or timing.
BAAR, SWITZERLAND · PolyPeptide Group AG media release on EGM results, distributed via EQS News, 26 Oct 2026
Physician Joseph Varon told The National News Desk that some patients have diarrhea years after stopping GLP 1 drugs. The report said causation was not shown, and the meaning of rodent thyroid tumor findings for people remains unknown.
UNITED STATES · The National News Desk interview with physician Joseph Varon, published by CBS12, 29 Oct 2026
Eli Lilly's third quarter revenue rose 39% to $24.4 billion as Mounjaro and Zepbound sales grew faster than prices fell, and the company raised its 2026 revenue forecast for a third time. The figures come from a Dow Jones report.
INDIANAPOLIS · Dow Jones report on Lilly third quarter 2026 results, published on Morningstar, 29 Oct 2026
Eli Lilly sold 53% more medicine by volume in the third quarter while realized prices fell 15%, lifting revenue 39% to $24.4 billion. About $900 million came from one time items, and the higher 2026 forecast is the company's own.
INDIANAPOLIS · Eli Lilly third quarter 2026 earnings release and investor presentation, 29 Oct 2026
Novo Nordisk will present 26 obesity abstracts in Washington from November 14 to 17, including REDEFINE 9 low dose CagriSema results and full STEP Young data in children. The announcement gives no efficacy or safety figures.
PLAINSBORO, NJ · Novo Nordisk press release via PR Newswire, 29 Oct 2026
UT Southwestern endocrinologist Jeffrey Zigman says the GLP 1 thyroid warning targets medullary thyroid carcinoma and MEN2, not common thyroid disease, and sets out how levothyroxine users can space doses around oral Wegovy and Foundayo.
DALLAS · UT Southwestern Medical Center expert article by endocrinologist Jeffrey Zigman, released via Newswise on 28 Oct 2026 and republished by News-Medical
Ascletis Pharma says its oral small molecule GLP 1 drug ASC30 lowered HbA1c by up to 1.7 points more than placebo in a 13 week U.S. Phase 2 study of 100 adults with type 2 diabetes. The data come from a press release and have not been peer reviewed.
HONG KONG · Ascletis Pharma press release via PR Newswire, 28 Oct 2026; ClinicalTrials.gov record NCT07321678
Corxel's merger with Amanat Acquisition Corp takes only its oral obesity candidates public, leaving stroke drug JX10 with a private parent. CX11 data so far come from company summaries without a placebo figure.
BERKELEY HEIGHTS, NJ · Corxel US and Amanat Acquisition Corp joint press release, 26 Oct 2026; BioPharma Dive interview with Corxel US CFO Kevin Xie, 26 Oct 2026
An interim HHS policy lets licensed pharmacies compound BPC 157, epitalon, KPV, MOTS c, Semax and TB 500 under ten conditions. None is FDA approved, FDA reviewers advised against listing them, and a final rule is still pending.
WASHINGTON · HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, posted Oct 27 to 28, 2026
An emergency physician told OMED that GLP 1 drugs drive most peptide visits but warned about melanotan and the BPC 157 and TB 500 stack. Some of his approval claims do not match current labels.
LAS VEGAS · OMED session by Kenneth L. Frye Jr., DO, Oct 22 to 25 2026, Las Vegas, as reported in a Healio interview, 28 Oct 2026
Lilly says retatrutide cut A1C by 2.2 points and weight by up to 20.9% at 80 weeks in type 2 diabetes, against 1.8 points and 9.4% on Ozempic. More people stopped retatrutide for side effects, and the data are not yet peer reviewed.
INDIANAPOLIS · Eli Lilly press release on TRANSCEND-T2D-2 topline results, 28 Oct 2026
Vanda Pharmaceuticals says its motion sickness drug Nereus lowered vomiting after a forced semaglutide dose in Phase 3, though the effect was smaller than in Phase 2 and full safety data are not public.
WASHINGTON · Vanda Pharmaceuticals press release on Study 3601, 27 Oct 2026
Vision loss suits against Eli Lilly and Novo Nordisk are pooled in a Philadelphia federal court. Europe calls NAION a very rare semaglutide side effect, but one large U.S. study found no clear rise in risk.
PHILADELPHIA · MedShadow report, 28 Oct 2026, with EMA PRAC statement of 6 Jun 2025 and JAMA journal studies
The FDA cleared insulin icodec for children aged 10 and older with type 2 diabetes, the first once weekly insulin for this group. The decision rests on adult trials and an 18 patient blood level study, not a pediatric efficacy trial.
SILVER SPRING, MD · FDA Drugs news item, 23 Oct 2026, with Novo Nordisk release of the same day
Two Phase 3 trials in The New England Journal of Medicine found Lilly's experimental retatrutide cut breathing pauses in 691 adults with obstructive sleep apnea, with and without type 2 diabetes. The drug is unapproved and heart outcomes were not tested.
BOSTON · The New England Journal of Medicine, Grunstein et al, TRIUMPH 1 OSA and TRIUMPH 2 OSA, DOI 10.1056/NEJMoa2611477, October 2026
A News-Medical research review says GLP 1 drugs show early but inconsistent signals in binge eating disorder, while a 45 member World Psychiatry panel backs screening every patient for eating disorders before treatment.
PUNE, INDIA · News-Medical research review, 26 Oct 2026; World Psychiatry Delphi consensus, Oct 2026; Eating and Weight Disorders meta-analysis, 2025
The 2026 KFF Employer Health Benefits Survey finds 18% of firms with 200 or more workers cover GLP 1 drugs for weight loss, flat on last year, while more covering firms now require lifestyle programs or counselling.
SAN FRANCISCO · KFF 2026 Employer Health Benefits Survey, published 22 Oct 2026; Business Group on Health survey as reported by SHRM, 25 May 2026
WADA left the status of GLP 1 drugs unchanged for 2027. Semaglutide and tirzepatide stay legal for athletes and on its Monitoring Program while two studies look at their effects in sport.
MONTREAL · WADA announcement of the 2027 Prohibited List (approved by the Executive Committee 10 Sep 2026), as republished by World Rugby, 6 Oct 2026
University of Queensland researchers say people injecting online peptides rarely see themselves as drug injectors and miss basic safety advice. NSW Health has warned hospitals of rising presentations, and needle programs report demand far above their contracts.
BRISBANE · The Conversation commentary by Akrigg, Ferris, Cornell and Piatkowski (University of Queensland), 26 Oct 2026; NSW Health Safety Information 009/26, 15 Oct 2026
At AAPS PharmSci 360, Dong-A ST reported a skin formulation of the oral psoriasis peptide icotrokinra that reached skin tissue and reduced inflammation in an animal model. No figures or human data were released.
NEW ORLEANS · Dong-A ST poster at AAPS PharmSci 360 2026, reported by Korea Biomedical Review, 27 Oct 2026; Johnson & Johnson release on Icotyde approval, 18 Mar 2026
Researchers at the Center for Science in the Public Interest say an FDA advisory committee vote backing six unapproved peptides, including BPC 157, for pharmacy compounding could undercut drug approval and put patients at risk.
WASHINGTON · JAMA Viewpoint by Samantaroy, Xu and Lurie (Center for Science in the Public Interest), published online 26 Oct 2026, doi 10.1001/jama.2026.19125
At Kidney Week 2026, investigator Hiddo Heerspink said AstraZeneca's oral GLP 1 drug elecoglipron lowered urine albumin in a phase 2 diabetes trial. A phase 3 kidney outcomes trial with about 7,000 people is now recruiting.
DENVER · Pharmacy Times interview with Hiddo Heerspink on ASN Kidney Week 2026 data, 26 Oct 2026; ClinicalTrials.gov records NCT06579105 and NCT07753993
A retrospective study presented at EASD 2026 found that 46.3% of adults with type 2 diabetes starting tirzepatide reached HbA1c below 6.5% at 12 months, against about one in five on semaglutide, GlobalData reported.
LONDON · GlobalData analysis of a real world study presented at the EASD 2026 Annual Meeting, 14 Oct 2026, reported by Longevity.Technology on 26 Oct 2026
A Translational Psychiatry study of 24,103 matched pairs found adults with obesity and major depression who started tirzepatide had a lower recorded risk of suicidal ideation than those on other obesity drugs. The authors say it is not proof of a protective effect.
TAINAN · Translational Psychiatry, Liu, Chu et al., published 25 Oct 2026, doi 10.1038/s41398-026-04518-0